Search
forLearn
5 / 801 resultslearn nonspecific group of glycoproteins
learn Phytosphingosine
learn Beta glucan
learn glutamic acid
Research
5 / 1000+ results
research Anthelminthic drugs
Some people have severe allergic reactions to anthelminthic drugs, but these are often due to the parasites, not the drugs.
research Epidermal keratinocytes initiate wound healing and pro-inflammatory immune responses following percutaneous schistosome infection
Epidermal keratinocytes start wound healing and inflammation after schistosome infection.
research Antigen presenting cells in the skin of a patient with hair loss and systemic lupus erythematosus.
Antigen presenting cells around hair follicles are crucial in SLE-related hair loss.
research Identification of neprilysin as a potential target of arteannuin using computational drug repositioning
Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.
research Antihelminthic Drugs
Antihelminthic drugs treat worm infections but face challenges like low treatment coverage and potential drug resistance, with various side effects reported for different drugs.
Community Join
5 / 1000+ resultscommunity mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community Expectations control for SCUBE3
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
community Best Treatment In The Pipeline?
New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.
community Clascoterone full results in July
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
community European release of clascoterone
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.